You have 9 free searches left this month | for more free features.

CLADRIBINE

Showing 51 - 75 of 172

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell Trial in China (Chidamide, Cladribine, Gemcitabine)

Recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, T-Cell
  • Deyang, Deyang, China
  • +10 more
Jul 21, 2022

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Trial (Cladribine)

Not yet recruiting
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • Cladribine
  • (no location specified)
Dec 17, 2020

Suboptimally Controlled Participants Previously Taking

Active, not recruiting
  • Multiple Sclerosis
  • Cladribine Tablets
  • Cullman, Alabama
  • +38 more
Jul 19, 2022

Acute Myeloid Leukemia Trial in Poland, United States (A arm (DA-90), B arm (DAC), A arm (CLAG-M))

Recruiting
  • Acute Myeloid Leukemia
  • A arm (DA-90)
  • +3 more
  • New York, New York
  • +9 more
Sep 30, 2021

Suboptimally Controlled Participants Previously Taking Oral or

Recruiting
  • Multiple Sclerosis
  • Cladribine Tablets
  • Cullman, Alabama
  • +66 more
Nov 29, 2022

Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Cladribine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2022

Multiple Sclerosis Trial in Worldwide (Cladribine, Placebo, Interferon-beta (IFN-beta))

Completed
  • Multiple Sclerosis
  • Cladribine
  • +2 more
  • Cullman, Alabama
  • +38 more
Oct 8, 2020

Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Cladribine, Placebo)

Completed
  • Relapsing-Remitting Multiple Sclerosis
  • Cladribine
  • Placebo
  • Boulder, Colorado
  • +116 more
Nov 10, 2020

Refractory Leukemia Trial in Shanghai (CALGE-VEN- RIC-MBF)

Recruiting
  • Refractory Leukemia
  • CALGE-VEN- RIC-MBF
  • Shanghai, Shanghai, China
  • +2 more
May 22, 2023

Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma Trial in Tucson (rituximab, bortezomib, cladribine)

Completed
  • Lymphoma
  • +3 more
  • Tucson, Arizona
    The University of Arizona Cancer Center
Dec 16, 2019

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

Registry of Multiple Sclerosis Participated in Cladribine

Completed
  • Multiple Sclerosis
    • Cambridge, Massachusetts
      Outcome Sciences, Inc
    Oct 24, 2019

    Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Trial in Houston (drug, other, biological)

    Recruiting
    • Hairy Cell Leukemia
    • Recurrent Hairy Cell Leukemia
    • Cladribine
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 20, 2020

    Acute Myeloid Leukemia Trial in Hangzhou (D-CLAG)

    Recruiting
    • Acute Myeloid Leukemia
    • D-CLAG
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital,School of Medicine, Zhejiang Unive
    Sep 12, 2020

    Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Tumor Trial in

    Completed
    • Blasts 10 Percent or More of Bone Marrow Nucleated Cells
    • +8 more
    • Cladribine
    • +13 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 11, 2021

    Acute Myeloid Leukemia, Relapse Leukemia Trial in Guangzhou (Cladribine, G-CSF, Aclarubicin)

    Unknown status
    • Acute Myeloid Leukemia
    • Relapse Leukemia
    • Cladribine
    • +3 more
    • Guangzhou, Guangdong, China
      Liang Wang
    Aug 18, 2019

    Acute Lymphoblastic Leukemia Trial in GuangZhou (Cladribine, G-CSF, Cytarabine)

    Unknown status
    • Acute Lymphoblastic Leukemia
    • Cladribine
    • +3 more
    • GuangZhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Aug 18, 2019

    Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in Seattle

    Completed
    • Acute Biphenotypic Leukemia
    • +5 more
    • Cladribine
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 26, 2019

    Acute Myeloid Leukemia Trial in Suzhou (IAC regimen, High-dose IA regimen, Intermediate-dose IA regimen)

    Recruiting
    • Acute Myeloid Leukemia
    • IAC regimen
    • +2 more
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Feb 3, 2020

    Multiple Sclerosis Trial in Worldwide (Mavenclad®)

    Completed
    • Multiple Sclerosis
    • Sydney, New South Wales, Australia
    • +53 more
    Jul 25, 2022

    Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Early Highly Effective Therapies Group
    • Escalation Therapies Group
    • Aurora, Colorado
    • +30 more
    Jul 22, 2022

    Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in

    Completed
    • Mixed Phenotype Acute Leukemia
    • +6 more
    • Cladribine
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Feb 21, 2020

    Multiple Sclerosis Trial in Worldwide (Cladribine, Placebo, Rebif® new formulation (RNF))

    Completed
    • Multiple Sclerosis
    • Cladribine
    • +2 more
    • Phoenix, Arizona
    • +157 more
    Feb 24, 2021

    Acute Myeloid Leukemia Trial in Saint Louis (Selinexor, Cladribine, G-CSF)

    Completed
    • Acute Myeloid Leukemia
    • Saint Louis, Missouri
      Washington University School of Medicine
    Mar 6, 2020

    Leukemia, Myeloid, Acute Trial in United States (DFP-10917, Cytarabine, Azacitidine)

    Recruiting
    • Leukemia, Myeloid, Acute
    • Birmingham, Alabama
    • +38 more
    Dec 25, 2021